Brief: Brickell Biotech Doses First Subject In Phase 1 Study Of Dyrk1a Inhibitor BBI-02
19/05/2022 15:36
Brickell Biotech Inc BBI.O :
* BRICKELL BIOTECH DOSES FIRST SUBJECT IN PHASE 1 STUDY OF
DYRK1A
INHIBITOR BBI-02
* BRICKELL BIOTECH INC - TOPLINE RESULTS FROM SAD AND MAD
PARTS OF
PHASE 1 STUDY EXPECTED TO BE ANNOUNCED BY EARLY 2023
Source text for Eikon: ID:nGNX1ChMPY
Further company coverage: BBI.O
Recent news on Fresh Tracks Therapeutics
See all newsBrief: Fresh Tracks Therapeutics Announces Second Adjournment Of Special Meeting Of Stockholders
Brief: Fresh Tracks Therapeutics Intends To Seek Judicial Dissolution If Liquidation And Approved By Stockholders
Brief: Fresh Tracks Therapeutics Q3 EPS USD 0.32
Brief: Fresh Tracks Therapeutics Inc On October 10 Received A Notice From Listing Qualifications Department Of Nasdaq
U.S. STOCKS ON THE MOVE-Gold miners, Goosehead Insurance, FedEx